Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings
Boston Scientific shares climbed 1.7% to $93.87 on Friday afternoon, rebounding from an earlier dip to $91.72.
Boston Scientific stock steadies after FDA flags AXIOS stent issue; Penumbra deal still in play
Shares of Boston Scientific Corporation held steady, edging just above $91.20 during late morning trading in New York on Wednesday.
Boston Scientific stock price slides again as $14.5B Penumbra deal puts debt, dilution in focus
Boston Scientific Corporation shares dropped 2.18% on Friday, closing at $88.07. It marked their seventh consecutive day of declines, with volume heavier than usual. The S&P 500 slipped 0.06%, the Dow fell 0.17%, and competitors Abbott and Medtronic also finished in the red.
Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy
Shares of Boston Scientific Corp dropped 1.8% to $88.44 Friday afternoon, deepening losses following its deal to acquire clot-removal specialist Penumbra. Meanwhile, Penumbra’s stock ticked up 0.3%, reaching $351.62.
Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next
Penumbra, Inc. shares jumped 11.8% to $350.49 in after-hours trading Thursday after Boston Scientific announced plans to acquire the clot-removal device maker in a roughly $14.5 billion deal. The stock reached an after-hours high of $369.84 but remained about $23 short of the $374 offer price, reflecting lingering merger risk and time before closing.
Boston Scientific’s $14.5B Penumbra Deal Leads a Busy Day for BSX, VZ, GS, MS and ASTS
Boston Scientific struck a deal to acquire Penumbra for roughly $14.5 billion on Thursday, drawing attention to the medical device sector. This move came amid Verizon’s ongoing outage issues and new earnings reports from Goldman Sachs and Morgan Stanley.
Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open
Boston Scientific announced Thursday it will acquire medical device maker Penumbra for roughly $14.5 billion in a cash-and-stock transaction, valuing Penumbra at $374 per share. Penumbra’s shares jumped over 13% in premarket trading. The offer comes at a 19.3% premium to Penumbra’s previous close, Reuters reported.